Literature DB >> 8233056

Magnesium and ketamine attenuate cognitive dysfunction following experimental brain injury.

D H Smith1, K Okiyama, T A Gennarelli, T K McIntosh.   

Abstract

We evaluated the therapeutic effects of two noncompetitive antagonists of the N-methyl-D-aspartate (NMDA) receptor, MgCl2 and ketamine, both individually and together, on cognitive dysfunction observed following parasagittal fluid-percussion (FP) brain injury in the rat. Using a modified Morris water maze technique, we found significant attenuation of post-traumatic memory dysfunction in animals treated with either MgCl2 (125 mumol) or ketamine (4 mg/kg) (P < 0.005). Combined MgCl2 and ketamine treatment also preserved memory function (P < 0.005), with no apparent additive effect.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8233056     DOI: 10.1016/0304-3940(93)90739-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

1.  N-methyl-D-aspartate receptor mechanosensitivity is governed by C terminus of NR2B subunit.

Authors:  Pallab Singh; Shachee Doshi; Jennifer M Spaethling; Adam J Hockenberry; Tapan P Patel; Donna M Geddes-Klein; David R Lynch; David F Meaney
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

2.  Dendritic alterations after dynamic axonal stretch injury in vitro.

Authors:  Hubert Monnerie; Min D Tang-Schomer; Akira Iwata; Douglas H Smith; Haesun A Kim; Peter D Le Roux
Journal:  Exp Neurol       Date:  2010-05-18       Impact factor: 5.330

Review 3.  Combination therapies for neurobehavioral and cognitive recovery after experimental traumatic brain injury: Is more better?

Authors:  Anthony E Kline; Jacob B Leary; Hannah L Radabaugh; Jeffrey P Cheng; Corina O Bondi
Journal:  Prog Neurobiol       Date:  2016-05-07       Impact factor: 11.685

Review 4.  Magnesium for neuroprotection in ischaemic stroke: rationale for use and evidence of effectiveness.

Authors:  K W Muir
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 5.  Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?

Authors:  Niklas Marklund; Lars Hillered
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat.

Authors:  Nicholas A Kaufman; Jason E Beare; Arlene A Tan; Michael P Vitek; Suzanne E McKenna; Michael R Hoane
Journal:  Behav Brain Res       Date:  2010-06-19       Impact factor: 3.332

7.  Acute treatment with the 5-HT(1A) receptor agonist 8-OH-DPAT and chronic environmental enrichment confer neurobehavioral benefit after experimental brain trauma.

Authors:  Anthony E Kline; Amy K Wagner; Brian P Westergom; Rebecca R Malena; Ross D Zafonte; Adam S Olsen; Christopher N Sozda; Pallavi Luthra; Monisha Panda; Jeffery P Cheng; Haris A Aslam
Journal:  Behav Brain Res       Date:  2006-12-12       Impact factor: 3.332

Review 8.  Using anesthetics and analgesics in experimental traumatic brain injury.

Authors:  Rachel K Rowe; Jordan L Harrison; Theresa C Thomas; James R Pauly; P David Adelson; Jonathan Lifshitz
Journal:  Lab Anim (NY)       Date:  2013-08       Impact factor: 12.625

9.  A 3D Tissue Model of Traumatic Brain Injury with Excitotoxicity That Is Inhibited by Chronic Exposure to Gabapentinoids.

Authors:  Nicolas Rouleau; Mattia Bonzanni; Joshua D Erndt-Marino; Katja Sievert; Camila G Ramirez; William Rusk; Michael Levin; David L Kaplan
Journal:  Biomolecules       Date:  2020-08-17

10.  A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.

Authors:  M S Milak; C J Proper; S T Mulhern; A L Parter; L S Kegeles; R T Ogden; X Mao; C I Rodriguez; M A Oquendo; R F Suckow; T B Cooper; J G Keilp; D C Shungu; J J Mann
Journal:  Mol Psychiatry       Date:  2015-08-18       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.